NEW YORK (GenomeWeb) – The recent addition of exosome technologies to the portfolio of Swiss multinational life sciences company Lonza reflects a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for non-invasive tests and new therapies.
Get the full story with
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.